Journal Guide

Current Neuropharmacology aims to provide current, timely and comprehensive reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.

Current Psychopharmacology publishes peer-reviewed expert full-length/mini reviews, original research articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology.

The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.

Current Therapeutic Research serves an international audience of scientists and clinicians in a variety of research, academic and clinical practice settings by quickly disseminating research findings. The journal provides a home for the rapid publication ofOriginal reports of recent development in drug therapy, including papers presenting unexpected, controversial, provocative and/or negative resultsResearch letters, presenting research that may stimulate further investigation or alert readers to clinically relevant but preliminary findingsIn-depth review articles on specific drug therapies or disease statesApplied health economics papers, aimed at a clinical audienceTrials From Resource-Limited Settings intended to highlight original medical and pharmaceutical reports from resource-limited settings.CTR is a peer-reviewed, author pays, online journal and the final published article will be universally accessible on all of Elsevier's platforms. In addition, the articles are indexed by all major biomedical abstracting databases.Published articles range from studies exploring new drugs and new indications for existing drugs to large, multicenter Phase III and IV trials. The journal also encourages submission of brief reports and commentaries on topics that are timely or provocative. For further information click on the links belowOriginal ResearchReview Articles and Meta-analysesCommentariesBrief ReportsResearch LettersLetters to the Editor

Current Treatment Options in Oncology offers in-depth review articles contributed by international experts on the most significant developments in the field.  By providing clear, insightful, balanced review articles that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the treatment of cancer.

The Drug Information Journal is the official publication of DIA. The scope of this peer-reviewed, scholarly publication is international and multidisciplinary. Its purpose is to disseminate information on manual and automated drug research, development, and information systems; to foster communication between educational, research, industrial, and governmental personnel engaged in drug information activities; and to provide a forum for the development of improved methods of presenting research data generated from chemical, toxicologic, pharmacologic, and clinical studies.

Drug Metabolism Letters publishes letters, original research articles, mini-reviews, thematic issues based on mini-reviews and letters, commentaries, technical notes and drug clinical trial studies on major advances in all areas of drug metabolism and disposition.

Drug Metabolism Reviews consistently provides critically needed reviews of an impressive array of drug metabolism research-covering established, new, and potential drugs; environmentally toxic chemicals; absorption; metabolism and excretion; and enzymology of all living species. Additionally, the journal offers new hypotheses of interest to diverse groups of medical professionals including pharmacologists, toxicologists, chemists, microbiologists, pharmacokineticists, immunologists, mass spectroscopists, as well as enzymologists working in xenobiotic biotransformation.

Thank you for your cooperation. (The degraded operation period has changed.

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance.It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine.Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research

Drug Safety is the official journal of the International Society of Pharmacovigilance. The journal includes:   

• Overviews of contentious or emerging issues. 
• Comprehensive narrative reviews that provide an authoritative source of information on epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. 
• In-depth benefit-risk assessment of adverse effect and efficacy data for a drug in a defined therapeutic area. 
• Systematic reviews (with or without meta-analyses) that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
• Original research articles reporting the results of well-designed studies in disciplines such as pharmacoepidemiology, pharmacovigilance, pharmacology and toxicology, and pharmacogenomics.
• Editorials and commentaries on topical issues.

Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.The rationale for this extensive coverage is the conviction that drug, alcohol and tobacco use/dependence cannot be understood in their entirety from a single perspective and that without an understanding of other areas of research, studies by individual investigators may be limited. The goal of the journal is to provide researchers, clinicians, and policy makers access to material from all perspectives in a single journal in a format that is understandable and which has received rigorous editorial review. The hope of its editors is to promote mutual understanding of the many facets of drug abuse to the benefit of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientific findings to successful treatment and prevention practices.The accepted abbreviation for Drug and Alcohol Dependence for bibliographic citation is Drug Alcohol Depend.Drug and Alcohol Dependence is currently being distributed to all the members of the College on Problems of Drug Dependence (CPDD), the oldest scientific organization in the United States concerned with research on problems of drug dependence. Members of the CPDD are provided with both the print version as well as access to the full text of the current issue and back issues dating back to Vol. 46, Issue no. 1 of the online version as a benefit of membership.

For nearly 50 years, DTB has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB was started in 1962. From the outset, it has provided healthcare professionals with independent, clear, reliable information and advice to help ensure patients get the best care. DTB conclusions represent a synthesis of the best available medical evidence with opinions from a wide range of commentators. Published monthly by BMJ, DTB is wholly independent of industry, Government and regulatory authorities and does not carry any display advertising or accept any form of commercial sponsorship.DTB provides articles based on a synthesis of evidence with opinions from a wide range of specialist and generalist commentators, typically over 40 individuals and organisations for each article. Over the years, DTB has initiated successful campaigns for the removal or restriction of medicines that it could not recommend, prompted withdrawal of excessive promotional claims and exposed fundamental weaknesses in certain prescribing practice.Surveys of our readership have consistently shown that readers find DTB authoritative and influential in relation to their decisions, recommendations or advice on treatments. These are just a few of the examples of why DTB is regarded as an indispensable part of evidence-based clinical practice and has been described as both essential reading for practising doctors and as a key information source by the House of Commons Health Select Committee in the UK.

Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 50 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original clinical research authored by leading international clinicians and researchers to support clinical decision-making.   

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

As a hybrid journal, Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require (more information).

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).